Effects of long-term treatment with testosterone on weight and waist size in 411 hypogonadal men with obesity classes I-III: observational data from two registry studies

• Published in: International Journal of Obesity Vol. 40; no. 1; pp. 162 - 170
• Main Authors: Saad, F, Yassin, A, Doros, G, Haider, A
• Format: Journal Article
• Language: English
• Published: London Nature Publishing Group UK 01.01.2016; Nature Publishing Group
• Subjects: 692/163; 692/699/2743/1526/1561; 692/699/2743/393; 692/700/2817; 692/700/478/174; 692/700/565/1331/238; Analysis; Androgens - blood; Androgens - therapeutic use; Atherosclerosis; Body mass index; Care and treatment; Complications and side effects; Epidemiology; Follow-Up Studies; Gastrointestinal surgery; Germany - epidemiology; Health aspects; Health Promotion and Disease Prevention; Humans; Hypogonadism - blood; Hypogonadism - drug therapy; Hypogonadism - metabolism; Influence; Internal Medicine; Male; Medicine; Medicine & Public Health; Men's Health; Metabolic Diseases; Middle Aged; Mortality; Obesity; Obesity - drug therapy; Obesity - metabolism; Obesity - prevention & control; Original; original-article; Prospective Studies; Public Health; Registries; Risk Factors; Testosterone; Testosterone - blood; Testosterone - therapeutic use; Time Factors; Treatment Outcome; Waist Circumference - drug effects; Weight Loss - drug effects; Germany; United States > US
• ISSN: 0307-0565; 1476-5497; 1476-5497
• DOI: 10.1038/ijo.2015.139

Background/Objectives: Long-term testosterone replacement therapy (TRT) up to 5 years has been shown to produce progressive and sustainable weight loss (WL) in hypogonadal men. This study investigated effects of long-term TRT up to 8 years in hypogonadal men with different obesity classes. Subjects/Methods: From two independent observational registries we identified a total of 411 obese, hypogonadal men receiving TRT in urological clinics. The effects of TRT on anthropometric as well as metabolic parameters were studied for a maximum duration of 8 years, mean follow-up: 6 years. All men received long-acting injections of testosterone undecanoate in 3-monthly intervals. Results: In all three classes of obesity, T therapy produced significant WL, decrease in waist circumference (WC) and body mass index (BMI). In patients with class I obesity, mean weight decreased from 102.6±6.4 to 84.1±4.9 kg, change from baseline: −17.4±0.5 kg and −16.8±0.4%. WC in this group of patients decreased from 106.8±7.4 to 95.1±5.3 cm, change from baseline: −10.6±0.3 cm. BMI decreased from 32.69±1.4 to 27.07±1.57, change from baseline: −5.52±0.15 kg m −2 . In patients with class II obesity, weight decreased from 116.8±6.9 to 91.3±6.3 kg, change from baseline: −25.3±0.5 kg and −21.5±0.4%. WC decreased from 113.5±7.5 to 100.0±5.4 cm, change from baseline: −13.9±0.4 cm. BMI decreased from 37.32±1.45 to 29.49±1.71, change from baseline: −8.15±0.17 kg m −2 . In patients with class III obesity, weight decreased from 129.0±5.6 to 98.9±4.8 kg, change from baseline: −30.5±0.7 kg and −23.6±0.5%. WC decreased from 118.5±5.6 to 103.8±4.9 cm, change from baseline: −14.3±0.4 cm. BMI decreased from 41.93±1.48 to 32.46±1.59, change from baseline −9.96±0.29 kg m −2 . Conclusions: Testosterone therapy appears to be an effective approach to achieve sustained WL in obese hypogonadal men irrespective of severity of obesity. Based on these findings we suggest that T therapy offers safe and effective treatment strategy of obesity in hypogonadal men.